Sökning: onr:"swepub:oai:gup.ub.gu.se/53902" >
Bone-targeted radiu...
-
Nilsson, S.Karolinska Institutet,Karolinska Hospital, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden
(författare)
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study
- Artikel/kapitelEngelska2007
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/53902
-
https://gup.ub.gu.se/publication/53902URI
-
https://doi.org/10.1016/S1470-2045(07)70147-XDOI
-
https://lup.lub.lu.se/record/645562URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-54164URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:115688596URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-49310URI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
BACKGROUND: The alpha-emitter radium-223 ((223)Ra) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone-refractory prostate cancer. We aimed to study mature outcomes from a randomised, multicentre, phase II study of (223)Ra. METHODS: Patients with hormone-refractory prostate cancer and bone pain needing external-beam radiotherapy were assigned to four intravenous injections of (223)Ra (50 kBq/kg, 33 patients) or placebo (31 patients), given every 4 weeks. Primary endpoints were change in bone-alkaline phosphatase (ALP) concentration and time to skeletal-related events (SREs). Secondary endpoints included toxic effects, time to prostate-specific-antigen (PSA) progression, and overall survival. All tests were done at a 5% significance level, based on intention to treat. FINDINGS: Median relative change in bone-ALP during treatment was -65.6% (95% CI -69.5 to -57.7) and 9.3% (3.8-60.9) in the (223)Ra group and placebo groups, respectively (p<0.0001, Wilcoxon ranked-sums test). Hazard ratio for time to first SRE, adjusted for baseline covariates, was 1.75 (0.96-3.19, p=0.065, Cox regression). Haematological toxic effects did not differ significantly between two groups. No patient discontinued (223)Ra because of treatment toxicity. Median time to PSA progression was 26 weeks (16-39) versus 8 weeks (4-12; p=0.048) for (223)Ra versus placebo, respectively. Median overall survival was 65.3 weeks (48.7-infinity) for (223)Ra and 46.4 weeks (32.1-77.4) for placebo (p=0.066, log rank). The hazard ratio for overall survival, adjusted for baseline covariates was 2.12 (1.13-3.98, p=0.020, Cox regression). INTERPRETATION: (223)Ra was well tolerated with minimum myelotoxicity, and had a significant effect on bone-ALP concentrations. Larger clinical trials are warranted to study (223)Ra on the prevention of SREs and on overall survival in patients with hormone-refractory prostate cancer. Bone-targeting properties of (223)Ra could also potentially be used for treating skeletal metastasis from other primary cancers.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Franzén, LarsFranzén, L., Länssjukhuset Sundsvall-Härnösand, Sundsvall, Sweden(Swepub:umu)lafr0004
(författare)
-
Parker, C.Institute of Cancer Research, Royal Marsden Hospital, Sutton, United Kingdom
(författare)
-
Tyrrell, C.Plymouth General Hospital, Plymouth, United Kingdom
(författare)
-
Blom, R.Östergötlands Läns Landsting
(författare)
-
Tennvall, JanLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,University Hospital Lund, Lund, Sweden(Swepub:lu)onk-jte
(författare)
-
Lennernäs, Bo,1963Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences,Lennernäs, B., Sahlgrenska University Hospital, Gothenburg, Sweden(Swepub:gu)xlennb
(författare)
-
Petersson, U.Centrallasarettet i Västerås, Västerås, Sweden
(författare)
-
Johannessen, D. C.Haukeland University Hospital, Bergen, Norway
(författare)
-
Sokal, M.Nottingham City Hospital, Nottingham, United Kingdom
(författare)
-
Pigott, K.Royal Free Hospital, London, United Kingdom
(författare)
-
Yachnin, J.Karolinska Institutet,Karolinska Hospital, Stockholm, Sweden
(författare)
-
Garkavij, MichaelLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,University Hospital Lund, Lund, Sweden(Swepub:lu)onk-mga
(författare)
-
Strang, P.Karolinska Institutet,Karolinska Institute, Stockholm, Sweden
(författare)
-
Harmenberg, J.Karolinska Institute, Stockholm, Sweden, Algeta ASA, Oslo, Norway
(författare)
-
Bolstad, B.Algeta ASA, Oslo, Norway
(författare)
-
Bruland, O. S.Bruland, Ø.S., University of Oslo, Norwegian Radium Hospital, Oslo, Norway
(författare)
-
Karolinska InstitutetKarolinska Hospital, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Lancet Oncol8:7, s. 587-5941470-20451474-5488
-
Ingår i:The Lancet Oncology8:7, s. 587-5941474-5488
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nilsson, S.
-
Franzén, Lars
-
Parker, C.
-
Tyrrell, C.
-
Blom, R.
-
Tennvall, Jan
-
visa fler...
-
Lennernäs, Bo, 1 ...
-
Petersson, U.
-
Johannessen, D. ...
-
Sokal, M.
-
Pigott, K.
-
Yachnin, J.
-
Garkavij, Michae ...
-
Strang, P.
-
Harmenberg, J.
-
Bolstad, B.
-
Bruland, O. S.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Lancet Oncol
-
The Lancet Oncol ...
- Av lärosätet
-
Göteborgs universitet
-
Lunds universitet
-
Umeå universitet
-
Karolinska Institutet
-
Linköpings universitet